Imatinib Completed Phase 2 Trials for Lung Cancer Metastatic / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Osteosarcoma / Childhood Desmoplastic Small Round Cell Tumor / Recurrent Neuroblastoma / Childhood Synovial Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Gastrointestinal Stromal Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00500188Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00025246Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
NCT00112632Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT01267695Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT00030667Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
NCT01483014Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
NCT00028002Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
NCT00455559Ph II Study of Perifosine Plus Gleevec for Patients With GIST
NCT00237172Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)